DK2290109T3 - Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira - Google Patents
Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-viraInfo
- Publication number
- DK2290109T3 DK2290109T3 DK10181786.4T DK10181786T DK2290109T3 DK 2290109 T3 DK2290109 T3 DK 2290109T3 DK 10181786 T DK10181786 T DK 10181786T DK 2290109 T3 DK2290109 T3 DK 2290109T3
- Authority
- DK
- Denmark
- Prior art keywords
- dengue viruses
- attenuation
- development
- well
- chimeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29304901P | 2001-05-22 | 2001-05-22 | |
EP02739358A EP1402075B1 (en) | 2001-05-22 | 2002-05-22 | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2290109T3 true DK2290109T3 (da) | 2014-11-10 |
Family
ID=23127420
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02739358.6T DK1402075T3 (da) | 2001-05-22 | 2002-05-22 | Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira |
DK10181776.5T DK2290108T3 (da) | 2001-05-22 | 2002-05-22 | Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira |
DK10181786.4T DK2290109T3 (da) | 2001-05-22 | 2002-05-22 | Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira |
DK10181804.5T DK2292802T3 (da) | 2001-05-22 | 2002-05-22 | Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira og kimære dengue-vira |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02739358.6T DK1402075T3 (da) | 2001-05-22 | 2002-05-22 | Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira |
DK10181776.5T DK2290108T3 (da) | 2001-05-22 | 2002-05-22 | Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10181804.5T DK2292802T3 (da) | 2001-05-22 | 2002-05-22 | Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira og kimære dengue-vira |
Country Status (8)
Country | Link |
---|---|
US (10) | US7226602B2 (da) |
EP (5) | EP2292802B1 (da) |
AU (2) | AU2002312011B2 (da) |
BR (2) | BR122019026154B8 (da) |
CA (5) | CA2755964C (da) |
DK (4) | DK1402075T3 (da) |
ES (4) | ES2399420T3 (da) |
WO (1) | WO2002095075A1 (da) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2338508B1 (en) | 2002-05-03 | 2018-02-14 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A rDEN3/4delta 30(ME), rDEN2/4delta30(ME) or rDEN1/4delta30(ME) recombinant chimeric dengue virus containing a 30 nucleotide deletion (delta30) in a section of the 3' untranslated region of dengue type 4 genome, wherein said 30 nucleotide deletion corresponds to the TL2 stem-loop structure |
EP1761277A1 (en) * | 2004-06-14 | 2007-03-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | West nile viruses with mutations in the 3' terminal stem and loop secondary structure for use as live virus vaccines |
EP1874346B1 (en) | 2005-04-24 | 2014-06-25 | Sanofi Pasteur Biologics, LLC | Recombinant flavivirus vaccines |
CN101238209B (zh) * | 2005-06-17 | 2013-02-13 | 赛诺菲巴斯德有限公司 | 登革血清型2减毒株 |
CA2611934C (en) | 2005-06-17 | 2015-11-03 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
CU23578A1 (es) * | 2005-09-16 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal |
FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
WO2008157136A1 (en) * | 2007-06-14 | 2008-12-24 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Chimeric sle/dengue type 4 antigenic viruses |
CA2716399C (en) | 2008-03-05 | 2020-07-21 | Pierre Chouvenc | Process for stabilizing an adjuvant containing vaccine composition |
EP2294192A4 (en) * | 2008-06-09 | 2011-11-23 | Jolla Inst Allergy Immunolog | COMPOSITIONS AND METHODS OF TREATMENT AND VACCINATION AGAINST DENGUE VIRUS (DV) |
EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
PE20110992A1 (es) | 2009-02-17 | 2012-02-12 | Glaxosmithkline Biolog Sa | Composicion inmunogenica que comprende un antigeno del virus del dengue |
WO2010130748A1 (en) * | 2009-05-12 | 2010-11-18 | Tibotec Pharmaceuticals | Method for identifying inhibitors against dengue virus |
EP2438198A4 (en) | 2009-06-01 | 2014-05-14 | Inviragen Inc | COMPOSITIONS AND METHODS FOR THE DELIVERY OF VACCINES AGAINST DENGUE VIRUS |
US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
JP2012529934A (ja) * | 2009-06-17 | 2012-11-29 | ウッドフォード,ステファン | 血行動態機能の測定 |
EP2473624B1 (en) | 2009-08-31 | 2019-05-01 | Gen-Probe Incorporated | Dengue virus assay |
EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
US10308689B2 (en) | 2010-06-24 | 2019-06-04 | La Jolla Institute For Allergy And Immunology | Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof |
US8895028B2 (en) | 2012-07-20 | 2014-11-25 | Arbovax, Inc. | Methods and compositions for dengue virus 3 (DV3) infectious clone |
EP2877208B1 (en) | 2012-07-24 | 2021-05-12 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
MX366154B (es) | 2013-06-21 | 2019-06-28 | Merck Sharp & Dohme | Composiciones de vacuna del virus del dengue y metodos de uso de las mismas. |
CA3212977A1 (en) | 2014-02-11 | 2015-08-20 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
MX2017002949A (es) * | 2014-09-05 | 2017-12-14 | Univ New York State Res Found | Arbovirus recodificado y vacunas. |
EP3236997B1 (en) | 2014-12-22 | 2024-05-29 | Merck Sharp & Dohme LLC | Dengue virus vaccine compositions and methods of use thereof |
JP6893174B2 (ja) * | 2015-01-16 | 2021-06-23 | タケダ ワクチン,インコーポレイテッド | 粒子に含まれる逆転写酵素活性の検出 |
EP3331559A4 (en) | 2015-08-03 | 2019-03-06 | The United States of America as represented by the Secretary of the Army, Walter Reed Army Institute Of Research (WRAIR) | PROTEIN OF RECOMBINANT DENGUE ENHANCING IMMUNITY |
BE1024160B9 (fr) | 2015-12-22 | 2017-12-06 | Glaxosmithkline Biologicals Sa | Formulation immunogène |
KR20180127397A (ko) * | 2016-03-11 | 2018-11-28 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 생약독화된 지카 바이러스 백신 |
TW202302144A (zh) | 2016-03-25 | 2023-01-16 | 美商威特拉公司 | 登革病毒的抗體分子之配方設計 |
EP3443077A4 (en) | 2016-04-14 | 2020-01-01 | National University of Singapore | FAST PROCESS FOR GENERATING LIVE ATTENUATED VACCINES |
WO2018129160A1 (en) | 2017-01-06 | 2018-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Live attenuated flavivirus vaccines and methods of using and making same |
AU2018346724A1 (en) | 2017-10-05 | 2020-05-14 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
WO2019112921A1 (en) | 2017-12-07 | 2019-06-13 | Merck Sharp & Dohme Corp. | Formulations of dengue virus vaccine compositions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5494671A (en) | 1990-08-27 | 1996-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | C-terminally truncated dengue and Japanese encephalitis virus envelope proteins |
IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
US6074865A (en) * | 1995-07-20 | 2000-06-13 | The United States Of America As Represented By The Secretary Of The Army | Recombinant dengue virus DNA fragment |
US6455509B1 (en) * | 1996-06-04 | 2002-09-24 | The United States Of America As Represented By The Secretary Of The Navy | Dengue nucleic acid vaccines that induce neutralizing antibodies |
JP2002540171A (ja) * | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱4型ウイルスワクチン |
ES2322327T3 (es) * | 1999-03-26 | 2009-06-19 | Walter Reed Army Institute Of Research | Vacuna multivalente contra el virus del dengue. |
-
2002
- 2002-05-22 CA CA2755964A patent/CA2755964C/en not_active Expired - Lifetime
- 2002-05-22 CA CA2966716A patent/CA2966716C/en not_active Expired - Lifetime
- 2002-05-22 DK DK02739358.6T patent/DK1402075T3/da active
- 2002-05-22 EP EP10181804.5A patent/EP2292802B1/en not_active Expired - Lifetime
- 2002-05-22 AU AU2002312011A patent/AU2002312011B2/en not_active Expired
- 2002-05-22 EP EP10181776.5A patent/EP2290108B1/en not_active Expired - Lifetime
- 2002-05-22 DK DK10181776.5T patent/DK2290108T3/da active
- 2002-05-22 EP EP02739358A patent/EP1402075B1/en not_active Expired - Lifetime
- 2002-05-22 WO PCT/US2002/016308 patent/WO2002095075A1/en not_active Application Discontinuation
- 2002-05-22 CA CA2448329A patent/CA2448329C/en not_active Expired - Lifetime
- 2002-05-22 DK DK10181786.4T patent/DK2290109T3/da active
- 2002-05-22 EP EP15150784.5A patent/EP2940154B1/en not_active Expired - Lifetime
- 2002-05-22 BR BR122019026154A patent/BR122019026154B8/pt not_active IP Right Cessation
- 2002-05-22 ES ES02739358T patent/ES2399420T3/es not_active Expired - Lifetime
- 2002-05-22 ES ES10181786.4T patent/ES2523168T3/es not_active Expired - Lifetime
- 2002-05-22 ES ES10181804.5T patent/ES2533085T3/es not_active Expired - Lifetime
- 2002-05-22 EP EP10181786.4A patent/EP2290109B1/en not_active Expired - Lifetime
- 2002-05-22 CA CA3060687A patent/CA3060687C/en not_active Expired - Lifetime
- 2002-05-22 BR BRPI0209943-8 patent/BRPI0209943B8/pt not_active IP Right Cessation
- 2002-05-22 DK DK10181804.5T patent/DK2292802T3/da active
- 2002-05-22 CA CA3114957A patent/CA3114957C/en not_active Expired - Lifetime
- 2002-05-22 ES ES10181776.5T patent/ES2512715T3/es not_active Expired - Lifetime
-
2003
- 2003-11-21 US US10/719,547 patent/US7226602B2/en not_active Ceased
-
2006
- 2006-06-02 US US11/446,050 patent/US7560118B2/en not_active Ceased
-
2008
- 2008-07-23 AU AU2008203275A patent/AU2008203275B2/en not_active Expired
-
2009
- 2009-03-02 US US12/396,376 patent/US8039003B2/en not_active Ceased
-
2011
- 2011-09-22 US US13/240,849 patent/US8632782B2/en not_active Expired - Lifetime
-
2013
- 2013-05-17 US US13/896,396 patent/USRE45016E1/en not_active Expired - Lifetime
- 2013-05-17 US US13/896,411 patent/USRE45053E1/en not_active Expired - Lifetime
- 2013-05-17 US US13/896,409 patent/USRE45123E1/en not_active Expired - Fee Related
- 2013-12-04 US US14/096,424 patent/US9707287B2/en not_active Expired - Lifetime
-
2017
- 2017-07-14 US US15/650,482 patent/US10500264B2/en not_active Expired - Lifetime
-
2019
- 2019-11-14 US US16/684,103 patent/US11318196B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2290109T3 (da) | Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira | |
DK1448523T3 (da) | Heterocycliske forbindelser samt metoder til anvendelse deraf | |
DK1386921T3 (da) | Mellemprodukter til fremstilling af anti-trombotiske 4H-cycolopenta-1,3-dioxol-derivater | |
DK1568367T3 (da) | Forbindelser, der påvirker glucokinase | |
DE60215848D1 (de) | 1,2,4-thiadiazolverbindungen als melanocortinrezeptor-modulatoren | |
NO20023283D0 (no) | Flammestopper | |
DK1651622T3 (da) | Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser | |
DK1505974T3 (da) | Anvendelse af forbindelser, der er effektive som selektive opiatreceptormodulatorer | |
ATE497953T1 (de) | Thiazolderivate als modulatoren des cannabinoidrezeptors | |
DK1296935T3 (da) | Fremgangsmåde til fremstilling af substituerede octanoylamider | |
DK1840125T3 (da) | Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater | |
DK1380121T3 (da) | Fremgangsmåde til fremstilling af oxazolidinoner | |
DK1401828T3 (da) | N-Formylhydroxylaminforbindelser som inhibitorer af PDF | |
DK1392318T3 (da) | 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse | |
DE602004014772D1 (de) | Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors | |
DE50205159D1 (de) | Zusammensetzungen enthaltend quaternäre Ammoniumverbindungen | |
DK1678135T3 (da) | Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser | |
DK1511724T3 (da) | Fremgangsmåde til fremstilling af thioalkylaminderivater | |
DK1503995T3 (da) | Fremgangsmåde til fremstilling af substituerede phenylsulfonylurinstoffer | |
DK1373232T3 (da) | Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner | |
DK1281707T3 (da) | Fremgangsmåde til fremstilling af 5-substituerede isobenzenfuraner | |
FR2822882B3 (fr) | Menuiserie de type etanche, particulierement pour usage civil | |
EE05246B1 (et) | Fungitsiididena kasutatavad oksasiin(ti)oonhendid | |
DK1685104T3 (da) | Fremgangsmåde til fremstilling af N-substituerede phthalomider | |
DK1692105T3 (da) | Fremgangsmåde til fremstilling af (3-oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-derivater |